Register HERE!

This is a very exciting time to be involved in cancer research! The 8th iteration of the Congress brings together international experts in oncology, immunobiology, pharmacology, molecular biology and molecular imaging to discuss preclinical, translational and clinical advances in diagnosing, treating and preventing cancer metastasis as we enter the era of precision medicine. With advancements in cancer care and patient-centered treatment planning, cancer survivors today live longer and enjoy a vastly improved quality of life than thought imaginable. We hope you will participate in 8th International Congress on Cancer Metastasis, scheduled for October 25-27, 2019 in San Francisco, California.

CME ACCREDITATION

Physicians:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and the Sentinel Node Oncology Foundation. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 16.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses:
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 16.30 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

TARGETED AUDIENCE

This activity is intended for physicians, residents, fellows, pharmacists, physician assistants, nurses, physical therapists, occupational therapists in the specialties of Plastic & Reconstructive Surgery, General Surgery, Breast Surgery, Medical Oncology, Radiation Oncology, and Lymphedema who treat or are involved in the treatment of patients with cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Identify cancer initiation and progression in the tumor microenvironment.
• Distinguish the pathways of metastasis by virtue of the lymphatic versus vascular systems.
• Recognize the utility of SLN biopsy in multiple cancers and that SLN may be the primary gateway to cancer metastasis.
• Describe the application of immune checkpoint inhibition to treat cancer.
• Integrate new genetic and mutational analysis information as biomarkers for diagnoses, staging and treatment selection for patients with metastatic cancers.
• Evaluate the potential application of molecular imaging for pinpoint stereotactic radiotherapy.
• Identify secondary lymphedema resulting from cancer treatment and methods to overcome lymphedema.